Bristol-Myers Squibb (BMY) Presents New Opdivo + Yervoy Data at IASLC 17th WCLC

November 16, 2016 5:14 PM EST

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Bristol-Myers Squibb Company (NYSE: BMY) announced new data to be presented at the International Association for the Study of Lung Cancer (IASLC) 17th World Conference on Lung Cancer (WCLC) in Vienna, Austria from December 4-7. Among the key data to be presented, studies evaluating Opdivo (nivolumab) monotherapy and in combination with Yervoy (ipilimumab) in two types of lung cancer highlight the company’s commitment to addressing high unmet medical needs.

Fouad Namouni, M.D., head of development, Oncology, Bristol-Myers Squibb, commented, “We believe Immuno-Oncology combinations may help improve outcomes for patients with lung cancer and have a strong scientific rationale for studying the Opdivo and Yervoy combination therapy. At the WCLC meeting, we will share data investigating this regimen in first-line non-small cell lung cancer and previously treated small cell lung cancer, as well as other important data from our broad thoracic development program.”

The full set of Bristol-Myers Squibb-sponsored data to be presented include:

  • First-line Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Patients With Advanced NSCLC: Long-term Outcomes From CheckMate -012Presenter: S. GettingerOral Session: Immunotherapy Checkpoint Inhibitors in Advanced NSCLC; Monday, December 5, 11:00 CET, Room C8
  • Nivolumab Alone or With Ipilimumab in Recurrent Small Cell Lung Cancer: Two-year Survival and Updated Analyses From the CheckMate -032 TrialPresenter: M. HellmannMini Oral Session: Immunotherapy Combinations; Tuesday, December 6, 14:50 CET, Room Strauss 2
  • Analysis of Early Survival in Patients With Advanced Non-squamous NSCLC Treated With Nivolumab vs Docetaxel in CheckMate -057Presenter: S. PetersOral Session: Immunotherapy Checkpoint Inhibitors in Advanced NSCLC; Monday, December 5, 11:45 CET, Room C8
  • Is Nivolumab Safe and Effective in Elderly and PS2 Patients With Non-small Cell Lung Cancer? Results of CheckMate -153Presenter: D. SpigelPoster Session with Presenters: Wednesday, December 7, 14:30 CET, Hall B
  • Demonstrating Life Expectancy Gains With Immuno-Oncology TherapiesPresenter: R. FiglinMini Oral Session: Immunotherapy in Advanced NSCLC: Biomarkers and Costs; Tuesday, December 6, 17:00 CET, Room Strauss 2
  • Prognostic Factors for Overall Survival Among Patients With Advanced/Metastatic Non-small Cell Lung CancerPresenter: K. VerlegerPoster Session with Presenters: Tuesday, December 6, 14:30 CET, Hall B
  • Checkmate 384: A Phase 3b/4 Dose-frequency Optimization Trial of Nivolumab in Advanced or Metastatic Non-small Cell Lung CancerPresenter: R. HarrisPoster Session with Presenters: Wednesday, December 7, 14:30 CET, Hall B

Bristol-Myers Squibb: At the Forefront of Immuno-Oncology Science & Innovation

At Bristol-Myers Squibb, patients are at the center of everything we do. Our vision for the future of cancer care is focused on researching and developing transformational Immuno-Oncology (I-O) medicines that will raise survival expectations in hard-to-treat cancers and will change the way patients live with cancer.

We are leading the scientific understanding of I-O through our extensive portfolio of investigational and approved agents, including the first combination of two I-O agents in metastatic melanoma, and our differentiated clinical development program, which is studying broad patient populations across more than 20 types of cancers with 11 clinical-stage molecules designed to target different immune system pathways. Our deep expertise and innovative clinical trial designs uniquely position us to advance the science of combinations across multiple tumors and potentially deliver the next wave of I-O combination regimens with a sense of urgency. We also continue to pioneer research that will help facilitate a deeper understanding of the role of immune biomarkers and inform which patients will benefit most from I-O therapies.

We understand making the promise of I-O a reality for the many patients who may benefit from these therapies requires not only innovation on our part, but also close collaboration with leading experts in the field. Our partnerships with academia, government, advocacy and biotech companies support our collective goal of providing new treatment options to advance the standards of clinical practice.

About Opdivo

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

Opdivo’s leading global development program is based on Bristol-Myers Squibb’s scientific expertise in the field of Immuno-Oncology and includes a broad range of clinical trials across all phases, including Phase 3, in a variety of tumor types. To date, the Opdivo clinical development program has enrolled more than 25,000 patients. The Opdivo trials have contributed to gaining a deeper understanding of the potential role of biomarkers in patient care, particularly regarding how patients may benefit from Opdivo across the continuum of PD-L1 expression.

In July 2014, Opdivo was the first PD-1 immune checkpoint inhibitor to receive regulatory approval anywhere in the world. Opdivo is currently approved in more than 57 countries, including the United States, the European Union and Japan. In October 2015, the company’s Opdivo and Yervoy combination regimen was the first Immuno-Oncology combination to receive regulatory approval for the treatment of metastatic melanoma and is currently approved in more than 47 countries, including the United States and the European Union.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News

Related Entities


Add Your Comment